FEC 60 adjuvant chemotherapy (ACT) in breast cancer (BC) patients (Pts): 5-year and 10-year follow-up results of a Brazilian single center institution

Silva, F. Moura; Laloni, M. T.; Tosello, C.; Bertozzi, A. P. A. P.; Carvalho, M. P.; Góes, J. C. G. S.

doi:10.1200/jco.2004.22.90140.835

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Cyclophosphamide, 5-Fluorouracil, and Epirubicin combination were mostly used for breast cancer treatment, as was reported by Dave et al (2014). This combination represents the most basic and effective chemotherapy combination according to the WHO essential drug list and has shown survival benefit (Russo et al, 2013;Silva et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

Anticancer drugs utilization for initiation phase of breast and cervical cancers chemotherapies in a Nigerian tertiary hospital

Adibe¹,

Aluh²,

Ma’aji³

2019

J App Pharm Sci

View full text Add to dashboard Cite

Background: Selection of anticancer drugs for initiation of chemotherapy is an important determinant of whether the patient would continue the chemotherapy, switch to another agent, or discontinue after the first course of chemotherapy. Therefore, it is important that attention should be given to the initiating agents, their side effects, and general safety of the patients. Objectives: This study assessed the utilization of anticancer drugs at the first course of breast and cervical cancers chemotherapies over a 5-year period (2012)(2013)(2014)(2015)(2016)

show abstract

Section: Discussionmentioning

confidence: 99%